Diadexus Revenue
Biotechnology Research • 
United States • 21-50 Employees
Diadexus revenue & valuation
| Annual revenue | $16,200,000 |
| Revenue per employee | $701,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $51,600,000 |
| Total funding | $15,000,000 |
Key Contacts at Diadexus
Colleen Quinn
National Sales Director
Tom Ricks
Senior Director Or Finance
Bill Carroll
National Sales Director
Company overview
| Headquarters | United States |
| Phone number | +16502466400 |
| Websites | |
| NAICS | 541714 |
| Founded | 1997 |
| Employees | 21-50 |
| Socials |
Diadexus Email Formats
Diadexus uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 45.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 45.6% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 22.3% |
{first name}@company.com | john@company.com | 15.1% |
{first name}{last name}@company.com | johndoe@company.com | 9.8% |
{first name}_{last name}@company.com | john_doe@company.com | 7.2% |
About Diadexus
A Multi-Product Company Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker’s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Diadexus has 11 employees across 5 departments.
Departments
Number of employees
Diadexus Tech Stack
Discover the technologies and tools that power Diadexus's digital infrastructure, from frameworks to analytics platforms.
Security
Ecommerce
JavaScript libraries
JavaScript libraries
CDN
Miscellaneous
Security
Programming languages
Analytics
UI frameworks
Cookie compliance
Font scripts
Austria
Canada
United Kingdom
Spain
Frequently asked questions
4.8
40,000 users
